What Is Talazoparib? Uses and Common Side Effects

Talazoparib is a targeted cancer drug that belongs to a class called PARP inhibitors. It works by blocking an enzyme your cells rely on to repair damaged DNA, and it does so more potently than other drugs in the same class. Approved for certain types of breast cancer and prostate cancer linked to specific genetic mutations, talazoparib has become an important option for patients whose tumors have faulty DNA-repair machinery. But the same mechanism that makes it effective against cancer also explains its most common side effect: low blood counts.

How Talazoparib Works

Your cells constantly sustain DNA damage from normal metabolic activity. An enzyme called PARP1 detects single-strand breaks in DNA and helps repair them. PARP inhibitors block that repair process, which matters most in cancers that already have a second DNA-repair pathway knocked out, such as tumors with BRCA1 or BRCA2 mutations. Without either repair route working, the cancer cell accumulates so much DNA damage that it dies.

What sets talazoparib apart from older PARP inhibitors is how strongly it “traps” the PARP enzyme on damaged DNA. Rather than simply preventing PARP from doing its job, talazoparib locks the enzyme in place on the DNA strand, creating a physical roadblock that is even more toxic to the cell than just losing the repair function. Among the five PARP inhibitors that have been used in the clinic, talazoparib produces the strongest trapping effect by a wide margin.¹ Laboratory experiments have shown that even at a dose one hundred times lower, talazoparib produces more trapping than weaker PARP inhibitors can achieve at much higher concentrations.² This potency is a double-edged sword: it makes talazoparib highly effective at killing cancer cells, but it also affects healthy cells that divide rapidly, especially those in bone marrow.

Approved Uses in Breast Cancer

Talazoparib was first approved for adults with certain advanced breast cancers that carry inherited BRCA1 or BRCA2 mutations and are HER2-negative. The pivotal trial behind this approval, called EMBRACA, compared talazoparib head-to-head with standard chemotherapy. Patients taking talazoparib went roughly twice as long before their disease worsened compared to those on chemotherapy.³

Beyond slowing cancer progression, talazoparib offered something chemotherapy often does not: a better day-to-day experience. In the EMBRACA trial, patients on talazoparib reported improved overall quality of life, while those on chemotherapy reported worsening quality of life. The time before patients experienced a meaningful decline in their well-being was about four times longer with talazoparib compared to chemotherapy.⁴ That quality-of-life advantage is a meaningful distinction from traditional chemotherapy, which typically causes nausea, hair loss, and fatigue at levels that can severely disrupt daily life. Talazoparib has its own side effects, but for many patients the experience is more manageable.⁵

Use in Prostate Cancer

More recently, talazoparib has gained approval in combination with enzalutamide (a hormone therapy) for men with metastatic castration-resistant prostate cancer. This is the form of prostate cancer that has stopped responding to standard hormone-blocking treatments and has spread to other parts of the body. The combination is used regardless of whether the tumor has identifiable DNA-repair gene mutations, though the benefit appears strongest in men whose tumors do carry such defects.

The large phase 3 trial behind this approval, called TALAPRO-2, showed that adding talazoparib to enzalutamide reduced the risk of disease progression or death by about a third in the overall study population.⁶ In patients whose tumors specifically had DNA-repair defects, the benefit was more dramatic, cutting the risk of progression by over half.⁷

Final overall survival data from the trial showed that the combination extended life by a median of nearly nine months compared to enzalutamide alone, at a median follow-up of about four and a half years. Median overall survival was roughly 46 months with the combination versus 37 months without it.⁸ That survival gain, confirmed in a well-powered randomized trial, is what makes this combination a standard treatment option for this patient population.

Common Side Effects

The most frequent side effects of talazoparib involve blood counts. This makes biological sense: the bone marrow is one of the most rapidly dividing tissues in your body, and talazoparib’s powerful PARP-trapping action affects healthy marrow cells along with cancer cells.⁹ In the EMBRACA breast cancer trial, about two-thirds of patients experienced some form of blood count drop.¹⁰ In the TALAPRO-2 prostate cancer trial, anemia and low neutrophil counts were the most common grade 3 or 4 side effects, affecting roughly half and a fifth of patients respectively.⁶

The three main hematologic side effects are:

Anemia: Low red blood cell counts, which can cause fatigue, shortness of breath, and dizziness. This is the single most common side effect across all talazoparib trials.
Neutropenia: Low white blood cell counts that raise infection risk. Patients are typically told to report fevers promptly.
Thrombocytopenia: Low platelet counts, which can lead to easy bruising or prolonged bleeding from minor cuts.

These blood count changes tend to appear within the first three to five months of treatment. In prostate cancer patients, the median time to a first episode of severe anemia was about two months from starting treatment, while severe low platelets could appear even sooner. Episodes of severe anemia and thrombocytopenia typically lasted about a week before resolving.¹¹ Your oncology team will monitor your blood counts regularly, especially during those first few months. Most patients can continue treatment with dose adjustments rather than stopping entirely. In the EMBRACA trial, about half of patients needed a dose reduction at some point, but fewer than 2% had to permanently stop talazoparib because of blood count problems.¹⁰

Non-blood-related side effects tend to be milder. The most commonly reported ones include nausea, decreased appetite, fatigue, and weakness. In the TALAPRO-1 prostate cancer study, about a third of patients experienced nausea, about a quarter had decreased appetite, and a similar number reported weakness. Most of these were mild to moderate in severity.¹¹

A Rare but Serious Long-Term Risk

All PARP inhibitors carry a warning about a small risk of developing myelodysplastic syndrome or acute myeloid leukemia, both cancers of the bone marrow. These are sometimes called therapy-related blood cancers. Post-marketing surveillance has raised enough concern that researchers have begun pooling data across trials to quantify the risk more precisely.¹² The absolute risk remains low, but it is not zero, and it is something your oncologist will discuss with you. The risk appears to be a class-wide effect of PARP inhibitors rather than unique to talazoparib, and it generally applies to patients who have been on treatment for a prolonged period.

Dosing, Kidney Function, and Drug Interactions

Talazoparib is taken as a once-daily oral capsule, a convenience compared to some older PARP inhibitors that require taking multiple pills twice a day.¹³ For breast cancer, the standard dose is 1 mg per day. For prostate cancer, it is used at a lower dose of 0.5 mg per day alongside enzalutamide.⁶

One practical consideration is kidney function. Talazoparib undergoes minimal processing by the liver, which means it does not interact with many common medications the way some other cancer drugs do. However, it is cleared partly through the kidneys, so your dose may need to be reduced if your kidneys are not working at full capacity. The current recommendations are the full dose for mild kidney impairment, a reduced dose of 0.75 mg for moderate impairment, and a starting dose of 0.5 mg for severe impairment.¹⁴ No dose changes are needed based on age, sex, body weight, or mild liver impairment.¹⁵

One drug interaction worth knowing about involves P-glycoprotein inhibitors. These are medications that interfere with a transport protein your body uses to move talazoparib out of cells. Common P-glycoprotein inhibitors include certain antifungals, heart rhythm drugs, and antibiotics. If you are taking one of these, your talazoparib dose will usually be reduced to 0.75 mg to prevent drug levels from climbing too high.¹⁵

How Talazoparib Compares to Other PARP Inhibitors

Five PARP inhibitors have been developed for clinical use: olaparib, rucaparib, niraparib, veliparib, and talazoparib. They all block the same enzyme, but they differ in how strongly they trap PARP on DNA, how they are processed by the body, and what off-target effects they produce. Talazoparib and niraparib have the longest half-lives among the group, which is why both can be given once daily.¹³

The structural differences between these drugs are not just academic. Research comparing all five has found that rucaparib and niraparib have more off-target activity against enzymes unrelated to PARP, while talazoparib, olaparib, and rucaparib inhibit a broader range of PARP family members. These selectivity differences may partly explain why each drug has a somewhat different side-effect profile in patients.¹⁶ In general, talazoparib’s much stronger PARP-trapping ability means it is effective at lower doses than the others, but it also tends to cause more bone marrow suppression.

When Talazoparib Stops Working

Like most targeted cancer therapies, talazoparib can lose effectiveness over time as tumors evolve resistance. The most well-understood resistance mechanism involves “reversion mutations” in BRCA genes. Here is what that means in plain terms: the cancer originally had a broken BRCA gene, which is what made it vulnerable to PARP inhibitors. Over time, some cancer cells acquire a new mutation that partially repairs the broken BRCA gene, restoring enough DNA-repair ability to survive despite the drug.

Researchers studying a patient whose cancer became resistant to talazoparib found that the tumor had developed two separate reversion mutations in BRCA2, each using a different deletion to restore the gene’s function. Both altered versions of the protein were predicted to be functional enough to resume DNA repair.¹⁷ The fact that multiple independent reversion events can occur simultaneously in different parts of the tumor makes resistance harder to overcome, because each cell population may need a different strategy to defeat it. This is a challenge shared across the entire PARP inhibitor class, not unique to talazoparib.

Combination With Immunotherapy

One of the more active areas of research involves pairing PARP inhibitors with immune checkpoint inhibitors. The rationale is that PARP inhibitors do more than just kill cancer cells directly. When they cause DNA damage, the cancer cell’s broken DNA fragments trigger an immune-signaling pathway that can attract immune cells to the tumor. PARP inhibitors also increase the number of abnormal proteins on the cancer cell surface, making it easier for the immune system to recognize the tumor as foreign. And they tend to raise levels of PD-L1, a protein that checkpoint immunotherapy drugs specifically target.¹⁸

Early research suggests this combination could even help patients whose tumors do not have BRCA mutations and would not typically respond well to PARP inhibitors alone. By amplifying DNA damage and making the tumor microenvironment more visible to the immune system, PARP inhibitors may broaden the pool of patients who benefit from immunotherapy.¹⁹ Clinical trials testing talazoparib with various checkpoint inhibitors are ongoing, and results so far are preliminary. This remains a promising but unproven strategy.

The Cost Question

Talazoparib is expensive, and cost-effectiveness analyses have reached different conclusions depending on the country and comparison being made. A study comparing talazoparib to standard chemotherapy for BRCA-mutated breast cancer found it cost-effective in both China and the United States, with the analysis in the US actually showing cost savings when factoring in the longer time patients stayed healthy and out of the hospital.²⁰ However, a German analysis found the picture far less favorable, with the cost per quality-adjusted life year gained exceeding €300,000, well above typical willingness-to-pay thresholds in European healthcare systems.²¹

For the prostate cancer combination of talazoparib plus enzalutamide, a US economic evaluation estimated total treatment costs over a patient’s lifetime at roughly $1.5 million compared to about $379,000 for enzalutamide alone. The added survival and quality-of-life gains were substantial, but the resulting cost per quality-adjusted life year exceeded $896,000.²² These numbers matter for insurance coverage decisions and vary significantly by country, but for individual patients the practical question is usually whether your insurer covers the drug and what your out-of-pocket share looks like. Patient assistance programs from the manufacturer exist, though navigating them requires coordination with your oncology team’s financial counselors.